Nippon Shinyaku Co Ltd
TSE:4516
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 789
5 298
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Nippon Shinyaku Co Ltd
Total Current Liabilities
Nippon Shinyaku Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nippon Shinyaku Co Ltd
TSE:4516
|
Total Current Liabilities
¥27.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Total Current Liabilities
¥2.4T
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Total Current Liabilities
¥643.9B
|
CAGR 3-Years
24%
|
CAGR 5-Years
14%
|
CAGR 10-Years
5%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Total Current Liabilities
¥747B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Total Current Liabilities
¥239B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Total Current Liabilities
¥1.1T
|
CAGR 3-Years
25%
|
CAGR 5-Years
18%
|
CAGR 10-Years
11%
|
|
Nippon Shinyaku Co Ltd
Glance View
Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.
See Also
What is Nippon Shinyaku Co Ltd's Total Current Liabilities?
Total Current Liabilities
27.7B
JPY
Based on the financial report for Sep 30, 2024, Nippon Shinyaku Co Ltd's Total Current Liabilities amounts to 27.7B JPY.
What is Nippon Shinyaku Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
7%
Over the last year, the Total Current Liabilities growth was -14%. The average annual Total Current Liabilities growth rates for Nippon Shinyaku Co Ltd have been 2% over the past three years , 3% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
